Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

SKYRIZI DIN 02572850

Status: Approved
Holder: ABBVIE CORPORATION
Molecule: RISANKIZUMAB

Health Canada record

Active ingredient(s)RISANKIZUMAB 55 MG
Dosage formSolution
RouteSubcutaneous
ScheduleSCHEDULE D; PRESCRIPTION
ClassHuman
ATCL04AC18 RIZANKIZUMAB
Original market date
Current status date16-Oct-2026
SourceHealth Canada DPD

Establishment licence of the holder

AbbVie Corporation — licence 101988, currently licensed, last inspection rating C (2023-07-18).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing RISANKIZUMAB

DINProductCompanyFormStrengthStatus
02532093SKYRIZIABBVIE CORPORATIONSolutionRISANKIZUMAB 360 MGMarketed
02519291SKYRIZIABBVIE CORPORATIONSolutionRISANKIZUMAB 150 MGMarketed
02519283SKYRIZIABBVIE CORPORATIONSolutionRISANKIZUMAB 150 MGMarketed
02546922SKYRIZIABBVIE CORPORATIONSolutionRISANKIZUMAB 90 MGApproved
02532107SKYRIZIABBVIE CORPORATIONSolutionRISANKIZUMAB 60 MGMarketed
02552507SKYRIZIABBVIE CORPORATIONSolutionRISANKIZUMAB 180 MGMarketed
02487454SKYRIZIABBVIE CORPORATIONSolutionRISANKIZUMAB 75 MGCancelled Post Market
Request a quote for SKYRIZI

How to read a Canadian DIN record